StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Cellectis Trading Up 2.2 %

CLLS opened at $2.56 on Friday. The firm has a market capitalization of $142.28 million, a price-to-earnings ratio of -1.53 and a beta of 3.12. The company’s 50 day simple moving average is $2.61 and its two-hundred day simple moving average is $2.66. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.20 and a quick ratio of 2.20.

Hedge Funds Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Principal Financial Group Inc. increased its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 424,533 shares of the biotechnology company’s stock after buying an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.